argyrotsipi/train-dataset huggingface dataset:
Topical Questions — House of Commons, 2015-11-16
Topic: Defense
Questions: More than 1,000 unaccompanied asylum-seeking minors have arrived in Kent this year, putting immense pressure on local services. Kent welcomes the Government’s commitment to increased funding, but foster homes are full so we need to find homes for those young people around the country. What steps are the Department taking to create a dispersal system for unaccompanied asylum seekers?; Despite the fact that we have the Regulation of Investigatory Powers Act 2000, the Data Retention and Investigatory Powers Act 2014 and the Counter-Terrorism and Security Act 2015, the Government are pushing through yet another Investigatory Powers Bill. Will the Home Secretary let us know whether commercial virtual private network providers will be classed as telecommunications operators under the Bill?; On behalf of my constituents, may I express our gratitude for the work of the security and intelligence services in protecting us from the sort of evil attacks that we have seen in Paris this weekend? Will the Minister for Security join me in publicly thanking those authorities whose work is usually done out of the public eye but is so important to our everyday lives?; In its inadequate judgment, Her Majesty’s inspectorate of constabulary found that Humberside police are not prepared to face their future financial challenges. Can the Home Secretary guarantee that there will be no more cuts in Humberside police’s funding that would further jeopardise their ability to deliver safety and security for my constituents?; A marauding terrorist firearms attack of the type we saw in Paris is a scenario the security services, police forces and others have trained and exercised for over a number of years. Will the Security Minister update the House on what lessons we might be able to learn from the terrible incidents in Paris to further protect the people of Great Britain?
John Henry Hayes (Conservative, Centre-right): There is always more to be learned from such events. The threat we face is dynamic, not static. France is one of our closest allies and we are working closely with it. The UK has a comprehensive approach to preparing for such tragic incidents, as demonstrated by the firearms exercise Strong Tower. As soon as the attacks happened, the police and agencies took steps to maintain the security of the UK. Prepared, fearless and certain: that is how we stand.
Topical Questions — House of Commons, 2015-11-16
Topic: Defense
Questions: More than 1,000 unaccompanied asylum-seeking minors have arrived in Kent this year, putting immense pressure on local services. Kent welcomes the Government’s commitment to increased funding, but foster homes are full so we need to find homes for those young people around the country. What steps are the Department taking to create a dispersal system for unaccompanied asylum seekers?; Despite the fact that we have the Regulation of Investigatory Powers Act 2000, the Data Retention and Investigatory Powers Act 2014 and the Counter-Terrorism and Security Act 2015, the Government are pushing through yet another Investigatory Powers Bill. Will the Home Secretary let us know whether commercial virtual private network providers will be classed as telecommunications operators under the Bill?; On behalf of my constituents, may I express our gratitude for the work of the security and intelligence services in protecting us from the sort of evil attacks that we have seen in Paris this weekend? Will the Minister for Security join me in publicly thanking those authorities whose work is usually done out of the public eye but is so important to our everyday lives?; In its inadequate judgment, Her Majesty’s inspectorate of constabulary found that Humberside police are not prepared to face their future financial challenges. Can the Home Secretary guarantee that there will be no more cuts in Humberside police’s funding that would further jeopardise their ability to deliver safety and security for my constituents?; A marauding terrorist firearms attack of the type we saw in Paris is a scenario the security services, police forces and others have trained and exercised for over a number of years. Will the Security Minister update the House on what lessons we might be able to learn from the terrible incidents in Paris to further protect the people of Great Britain?
John Henry Hayes (Conservative, Centre-right): It is critically important that they have the resources, but they also need the right powers. That is precisely why we are bringing together those powers—they have been mentioned several times during this question session—in a clear, transparent and comprehensive way. This is a balance between giving those who are missioned to keep us safe what they need to do the job, and having the right checks and balances in place to maintain the role of this House in holding Ministers to account for the exercise of those functions.
Paris Terrorist Attacks — House of Commons, 2015-11-16
Topic: Defense
Julian Murray Lewis (Conservative, Centre-right): No coherent military strategy against Daesh/ISIL in Syria can be formulated unless and until the Government face up to the unpleasant fact that they will have to co-ordinate their efforts with those of Russia. Would a useful first step be co-operation between the Russian security services and ours in this field, despite our reservations and concern about Russia’s behaviour in other parts of Europe?
Paris Terrorist Attacks — House of Commons, 2015-11-16
Topic: Health
Michael Louis David Fabricant (Conservative, Centre-right): My right hon. Friend has mentioned the 129 murdered and the hundreds still in hospital, but in addition there are people like a friend of mine, who on Friday night was in a bistro just yards from the café that was attacked. He and two English friends—he is English too—escaped and ran down the road, only to find themselves getting very close to another area, the Bataclan, which was under attack. He has now returned home, and I can tell my right hon. Friend and the House that he is totally traumatised. Will she work across Government to ensure that people like him and others who have returned to the UK who have been hurt in this way will receive assistance from the Department of Health and other organisations?
Paris Terrorist Attacks — House of Commons, 2015-11-16
Topic: Defense
Theresa Mary May (Conservative, Centre-right): My hon. Friend is right. I first met Sir Peter Ricketts when he was the national security adviser, so he is well aware of the issues of national security and counter-terrorism work. He has done an outstanding job as our ambassador in France. I worked closely with him in the summer on the issue in Calais, and he and his staff have worked tirelessly over the weekend to ensure that consular support was available to those British families who were caught up in the terrible attacks, and that every assistance was given to the French authorities in the work that they were doing.
Paris Terrorist Attacks — House of Commons, 2015-11-16
Topic: Defense
Theresa Mary May (Conservative, Centre-right): I assure the hon. Lady that there are tried and tested arrangements in place for military support to be provided to the police when necessary. We looked at this issue again after the attacks in Paris earlier this year. Exercise Strong Tower took place on the streets of London this summer. Hundreds of individuals took part in the exercise, which involved not just the police but the military.
Dangerous Driving: Sentencing — House of Commons, 2015-11-03
Topic: Health
Michael Penning (Conservative, Centre-right): I am aware of the scheme, and I discussed it with the Prime Minister only recently. I believe that one of the sobriety bracelets that are being used in Croydon is on the Prime Minister’s desk as we speak. I am encouraging PCCs around the country to push this measure forward, as it has been very successful. I congratulate those who are pushing it forward.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
George William Freeman (Conservative, Centre-right): The debate on Second Reading raised a large number of issues, which clearly need to be addressed and I have no doubt will be addressed in Committee. We cannot second-guess where that Committee will get to or the shape of any Bill that might subsequently return to the Floor of the House The costs associated with this Bill, were it to be implemented in its current shape, arise from the establishment and maintenance of a database by the Health and Social Care Information Centre. Early discussions on costing with the HSCIC, which is leading on the construction of a number of databases and data streams crucial to the operation of the NHS, have provided an indicative costing of between £5 million and £15 million for developing the database of innovative medicines that the Bill anticipates.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
John Charles Baron (Conservative, Centre-right): My hon. Friend has implied broad Government support for the Bill. Can he provide any evidence to suggest that litigation is preventing doctors from innovating in medical science and practice generally? That is the premise on which the Bill is based.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
George William Freeman (Conservative, Centre-right): My hon. Friend makes a good point. That is the premise on which the Bill introduced by Lord Saatchi in the other place earlier in the year in the previous Parliament was predicated. My hon. Friend is right that it is a controversial proposition that fear of litigation for medical negligence is putting clinicians off innovating. The evidence that the Government received through the consultation was that some clinicians do feel that that is a problem, but very few saw it as the principal problem or the principal obstacle. A number of clinicians made the point that several factors have acted in recent decades to slow down the rate of innovative prescribing and other procedures in surgery and elsewhere, not least increasing central control of procurement from NHS England, which puts in place very tight procurement guidelines, as well as a general sense of an increasingly litigious society, which is just one of a number of factors cited in an extensive range of barriers to innovation.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
George William Freeman (Conservative, Centre-right): The hon. Lady makes a series of interesting points. Her criticisms would perhaps apply more to the Bill introduced by Lord Saatchi in the other House. Let me confirm that this Bill has nothing at all to do with clinical research. It is to do with clarifying the freedoms that she is right to say that clinicians enjoy today. Clinicians are free to prescribe any treatment for their patients that they feel is appropriate on the basis of the clinical evidence The specific problem that the Government recognise, whether or not this Bill is the appropriate mechanism to deal with it, is that in order for clinicians to feel confident in making an innovative prescription or adopting an innovative procedure, the biggest barrier is the lack of information on what innovative procedures are out there already and being used by other clinicians. It was with that in mind that the registry was originally proposed in the Bill introduced by Lord Saatchi. It was originally intended as a registry of innovative practices that clinicians adopted under the procedures in the Bill, which merely clarify the existing protections already afforded by medical negligence law. It was felt that that registry would be a helpful innovation in itself The Government’s view is that, as we build an infrastructure for the provision of information to clinicians to support off-label use of medicines and access to the latest information on innovative treatments, that registry could provide a much more interesting function of providing to clinicians, at the click of a mouse, an up-to-date registry of innovative medicines that are available and off-label and other treatments that other clinicians are already using. I want to stress that this Bill, which has a very different structure from the original Bill introduced by Lord Saatchi, has nothing to do with research at all. It is purely to do with supporting innovative prescribing by clinicians by providing them with information on innovations that they might consider.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
George William Freeman (Conservative, Centre-right): I want to make two things absolutely clear. First, this Bill, in law, would have no impact at all on clinical research. We in the Department have been very clear about that. If it in any way changed the basis on which clinical research is regulated, it would be a very serious matter, because we lead the world in terms of our ethical and regulatory controls on research, and it is vital that we do not affect that Secondly, it would be a matter of very serious concern if this Bill were to undermine patient or public trust and confidence in our NHS, our research medicine and our clinical trials infrastructure. I flagged up on Second Reading the fact that I do have some concerns. Some of those relate to the way in which this debate is conducted, although I am not making any comment about the hon. Lady’s intervention. It is very important that we explain to people what this Bill does and does not do. If we mislead them, it is not surprising that we will get a lot of unnecessary fear. It is very important that we clarify that this has nothing to do with clinical research.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
Sarah James (Wollaston) (Conservative, Centre-right): Does the Minister accept, however, that the Association of Medical Research Charities, the Academy of Royal Medical Colleges, the British Medical Association, and an A to Z of other organisations involved with medical research are very clear that this does undermine participation in medical research? He should listen to those concerns and acknowledge that they are genuine.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
George William Freeman (Conservative, Centre-right): Yes, indeed; I have listened. I acknowledged those concerns on Second Reading and said I was concerned about them. This is merely a debate about the Bill—there is no change in the law—and it is only this debate that is upsetting people at the moment. It is therefore very important that we carry it out in a way that makes it clear to them what this Bill does and does not achieve I am concerned that the passage of the Bill, the conduct of the debate, and any legislation that may survive the process of parliamentary scrutiny do not in any way undermine public or patient trust and confidence in clinical research or mainstream medicine. Were it to do so, I would be very concerned and the Government would be unable to support it. I have made it very clear to my hon. Friend the Member for Daventry that that is the No. 1 consideration, and as this is his private Member’s Bill, it is his task to get it to a point at which the Government would feel able to support it. Public trust and confidence in our NHS and in our clinical research infrastructure is crucial.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
John Charles Baron (Conservative, Centre-right): May I add to the voice of my hon. Friend the Member for Totnes (Dr Wollaston) and suggest that not just the bodies she mentioned but many of the cancer bodies, charities and communities are very concerned about this Bill? Let me bring the Minister back to the issue of evidence. The pursuit of justice starts with evidence, and there is no evidence that litigation is deterring doctors from innovating. This Bill, in many respects, addresses a non-existent problem. If it is not necessary to legislate, it is necessary not to legislate.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
Christopher Heaton-Harris (Conservative, Centre-right): I thank the Government for introducing, as is the convention of this place, the money resolution on my private Member’s Bill Several colleagues have expressed their concerns about the Bill, as the Opposition spokesman has just done. I must say to them, and to the Association of Medical Research Charities and other bodies, that many of the briefings seem to relate to the previous iteration of the Saatchi Bill that went through three Readings in the other place and have not been changed for this Bill, even though this Bill is massively different from that brought forward by Lord Saatchi in the House of Lords The Bill has two elements. It proposes that a database of innovation be established for only registered medical practitioners to use when they innovate or depart from standard medical practice. As we have already heard, doctors and surgeons say that they regularly innovate.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
Phillip James Lee (Conservative, Centre-right): I would never question my hon. Friend’s intentions in this area, but the AMRC’s summary states: "we do not see the need for this legislation and do not believe the Bill will achieve its aim of encouraging medical innovation." It goes on to say that "this Bill…as it stands is unnecessary and may adversely impact on patients and medical research". That view is supported, among others, by Cancer Research UK, the British Heart Foundation and the Wellcome Trust. Does that not give him pause for thought before he proceeds with the Bill?
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
Christopher Heaton-Harris (Conservative, Centre-right): Yes, it does. I have talked to those organisations constantly from the conception of the idea of stealing these two ideas from the Saatchi Bill, and I will continue to talk to every organisation that wishes to talk to me about the Bill. If that was a bid to be on the Bill Committee to offer an alternative view and help me pick through the details of the legislation to ensure that it does what I intend it to do, I welcome my hon. Friend’s approach because a couple of people who would have added great value to the process and the Bill are not able to sit on the Committee I gave the example on Second Reading of a surgeon who had innovated and saved the life of his patient, but who was unable quickly to communicate that to his peers as there was no comprehensive means of doing so. The database has been called for by many of the medical colleges, as is acknowledged in the briefings that my hon. Friend will have read. The database is important in spreading the best innovations, because it will include not just the successes of any innovation, but its failures. That will allow best practice to spread quickly and for other registered medical practitioners to learn from any innovation. It will not be available for patients to access and will be held by the Health and Social Care Information Centre, as we have just heard, which is where the money resolution directs the money towards The database will not cover research and will not hamper recruitment to clinical trials. Nothing in the Bill will allow doctors to bypass any process or requirement that has been set by their trust in relation to undertaking innovative treatments in the NHS, including the requirement to ensure that commissioners will fund any treatment that is not provided by the NHS. As we all know, individual innovation is incredibly important, but it is not a suitable substitute for medical research, which usually tests the efficacy of treatments in a systematic way. I hope that successful innovations will lead to systematic research projects as the evidence builds around a particular specialty and that they will thereby encourage more clinical trials The second part of the Bill, which I fully acknowledge is much more controversial, will give registered medical practitioners a supplementary method of demonstrating that they have acted responsibly while innovating. It closely mirrors the existing legal test, the Bolam test, that is used when clinical negligence proceedings reach the court stage. It brings the test forward and enables doctors to use it to demonstrate that they have acted responsibly before they enter the courtroom. It does not change the common law.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
John Charles Baron (Conservative, Centre-right): I fully respect the good intentions behind the Bill and those of my hon. Friend. I suggest to him that his last point perhaps misses the more fundamental point that it is the fear of litigation that may deter doctors and medical professionals generally from innovating, and thereby put patients at risk. Does he accept that that is at least a valid concern?
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
Christopher Heaton-Harris (Conservative, Centre-right): I am not convinced that that is the case because doctors and registered medical practitioners innovate daily across the national health service. Litigation might be a consideration in the back of their minds, but they are all responsible doctors doing the best for their patients. I do not quite see my hon. Friend’s point Doctors have to demonstrate that they have acted responsibly and that remains the case under my Bill. If they have not acted responsibly, they will be subject, as they are now, to the full force of medical negligence law and bodies such as the General Medical Council I would argue that my Bill provides extra safeguards to protect patients from medics who peddle treatments that are dangerous or misguided. First, any doctor must act responsibly and in the best interests of his or her patients. They must also be able to demonstrate that they have done so—as they do now—if it gets to a court of law. Secondly, when an innovation is listed on the database, its successes and failures have to be listed. If a rogue doctor’s peers are able quickly to see the exact results of their innovation, would that doctor not be almost exposing themselves and their quackery to their peers My Bill has massively evolved from Lord Saatchi’s Medical Innovation Bill from which many of the criticisms levelled against it come. I have been working with the Department of Health, and others, to ensure that the Bill achieves its central aim, and I know that I have a long road ahead should the Bill get through Committee and its other stages. I fully intend to work with everybody who wishes to make suggestions and help constructively so that we can get to a point where we have a database of innovation that can help spread best practice across our NHS.
Access to Medical Treatments (Innovation) Bill (Money) — House of Commons, 2015-11-03
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): I support everything the hon. Lady has just said. I was a research nurse in cancer care for more than 10 years. We observed good clinical practice standards, and the standards of the Medicines and Healthcare Products Regulatory Agency and the FDA, because mistakes happened. Those safeguards are in place for a reason. The No. 1 reason is to protect the patient.